We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

This was the stock's second consecutive day of gains.

A month has gone by since the last earnings report for Vertex Pharmaceuticals (VRTX). Shares have added about 7.3% in that time frame, outperforming the S&P 500. Will the recent positive trend ...

Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) was upgraded by analysts at StockNews.com from a “hold” rating to a ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

The stock's fall snapped a four-day winning streak.

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

Learn more about whether Riot Platforms, Inc. or Vertex, Inc. is a better investment based on AAII's A+ Investor grades, ...

Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...

Vertex's success since the early 2010s is due to its work in CF. The company famously markets the only approved medicines that target the underlying causes of this condition. Thanks to its monopoly, ...

Why is China the Talk of the Town in […] Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. The Nasdaq Composite Index ...